Problem

Many potent protein medicines are administered systemically, so they remain active throughout the body even when the disease is localized to one tissue. That creates safety issues, dose limitations, and a narrow therapeutic window: clinicians may be unable to deliver enough drug to achieve efficacy, particularly in combination regimens, while highly potent immune stimulators can be too toxic to develop or use effectively. The company’s clearest use case is cancer immunotherapy, where powerful treatments show promise but are constrained by toxicity and dose ceilings.

Product / Service

SynsoryBio is developing a synthetic-biology drug platform that builds “if-then” logic into protein therapeutics. A drug is designed to sense a disease-associated biomolecule and activate only when that signal is present, allowing it to remain comparatively inactive elsewhere in the body. The approach is intended to make clinically tested cancer immunotherapies safer and more effective by concentrating activity at diseased tissue, while also being adaptable to other proteins, biomarkers, cancers, and autoimmune diseases.

Market

SynsoryBio competes in synthetic biology and biotech therapeutics, with an initial focus on oncology and a broader potential application in autoimmune disease. Its competitive set is best understood as adjacent rather than molecule-for-molecule: Tracxn names Jazz Pharmaceuticals, BeiGene, and Sana Biotechnology among its top competitors, although those companies have broader biopharmaceutical, immune-oncology, or cell-therapy businesses rather than an identical conditional-activation platform.

The company appears to be an early-stage, pre-commercial biotech rather than a clinically validated product company. It was founded in 2023, joined Y Combinator’s Winter 2024 batch, and is listed as active with a two-person team. Publicly reported financing totals $500,000 across two rounds, including a Y Combinator seed round and an NSF grant; the cited materials disclose no clinical trial, approved product, revenue, or commercial partnership traction, so its current traction is primarily platform development, fundraising, and scientific outreach.